Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Bullboard Posts
Post by adogsbodyon Jun 21, 2004 9:00am
167 Views
Post# 7632585

Current Ratio

Current Ratio Current Asssets 2003 Jan 31 $ 402K Current Liabilities 1363K Assets as a % of Liabs is 29% Current Assets 2004 Jan 31 $ 223K Current Liabilities 1235K Assets as a % of Liabs is 18% Continued further deterioration of an already bad ratio I would hate to be in the payables department here. If you want payment the answer will be "take a number"
Bullboard Posts